Retinal Disorders Therapy Industry Research Report 2025
Description
Summary
According to APO Research, The global Retinal Disorders Therapy market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Retinal Disorders Therapy include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Retinal Disorders Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Disorders Therapy.
The Retinal Disorders Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Retinal Disorders Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Retinal Disorders Therapy Segment by Company
ALLERGAN
Alimera Sciences
Bausch & Lomb
Bristol-Myers Squibb
Genentech
Genzyme
Janssen Biotech
OCULAR THERAPEUTIX
Swedish Orphan Biovitrum
UCBCares
AbbVie
Eyebright Medical
Aier Eye Hospital
Alcon Holdings, Inc.
Huaxia Eye Hospital
Kanghong Pharmaceutical
Roche
Xingqi Pharmaceutical
Retinal Disorders Therapy Segment by Type
Ocular Inflammatory Disease (Uveitis)
Diabetic Retinopathy
Age Related Macular Degeneration
Macular Hole
Retinal Disorders Therapy Segment by Application
Hospitals
Clinics
Others
Retinal Disorders Therapy Segment by Application
Hospitals
Clinics
Others
Retinal Disorders Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Disorders Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinal Disorders Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Disorders Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Retinal Disorders Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Retinal Disorders Therapy market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Retinal Disorders Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Retinal Disorders Therapy include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Retinal Disorders Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Disorders Therapy.
The Retinal Disorders Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Retinal Disorders Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Retinal Disorders Therapy Segment by Company
ALLERGAN
Alimera Sciences
Bausch & Lomb
Bristol-Myers Squibb
Genentech
Genzyme
Janssen Biotech
OCULAR THERAPEUTIX
Swedish Orphan Biovitrum
UCBCares
AbbVie
Eyebright Medical
Aier Eye Hospital
Alcon Holdings, Inc.
Huaxia Eye Hospital
Kanghong Pharmaceutical
Roche
Xingqi Pharmaceutical
Retinal Disorders Therapy Segment by Type
Ocular Inflammatory Disease (Uveitis)
Diabetic Retinopathy
Age Related Macular Degeneration
Macular Hole
Retinal Disorders Therapy Segment by Application
Hospitals
Clinics
Others
Retinal Disorders Therapy Segment by Application
Hospitals
Clinics
Others
Retinal Disorders Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Disorders Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinal Disorders Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Disorders Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Retinal Disorders Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
127 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Retinal Disorders Therapy by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Ocular Inflammatory Disease (Uveitis)
- 2.2.3 Diabetic Retinopathy
- 2.2.4 Age Related Macular Degeneration
- 2.2.5 Macular Hole
- 2.3 Retinal Disorders Therapy by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Retinal Disorders Therapy Breakdown Data by Type
- 3.1 Global Retinal Disorders Therapy Historic Market Size by Type (2020-2025)
- 3.2 Global Retinal Disorders Therapy Forecasted Market Size by Type (2026-2031)
- 4 Retinal Disorders Therapy Breakdown Data by Application
- 4.1 Global Retinal Disorders Therapy Historic Market Size by Application (2020-2025)
- 4.2 Global Retinal Disorders Therapy Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Retinal Disorders Therapy Market Perspective (2020-2031)
- 5.2 Global Retinal Disorders Therapy Growth Trends by Region
- 5.2.1 Global Retinal Disorders Therapy Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Retinal Disorders Therapy Historic Market Size by Region (2020-2025)
- 5.2.3 Retinal Disorders Therapy Forecasted Market Size by Region (2026-2031)
- 5.3 Retinal Disorders Therapy Market Dynamics
- 5.3.1 Retinal Disorders Therapy Industry Trends
- 5.3.2 Retinal Disorders Therapy Market Drivers
- 5.3.3 Retinal Disorders Therapy Market Challenges
- 5.3.4 Retinal Disorders Therapy Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Retinal Disorders Therapy Players by Revenue
- 6.1.1 Global Top Retinal Disorders Therapy Players by Revenue (2020-2025)
- 6.1.2 Global Retinal Disorders Therapy Revenue Market Share by Players (2020-2025)
- 6.2 Global Retinal Disorders Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Retinal Disorders Therapy Head Office and Area Served
- 6.4 Global Retinal Disorders Therapy Players, Product Type & Application
- 6.5 Global Retinal Disorders Therapy Manufacturers Established Date
- 6.6 Global Retinal Disorders Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Retinal Disorders Therapy Market Size (2020-2031)
- 7.2 North America Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Retinal Disorders Therapy Market Size by Country (2020-2025)
- 7.4 North America Retinal Disorders Therapy Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Retinal Disorders Therapy Market Size (2020-2031)
- 8.2 Europe Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Retinal Disorders Therapy Market Size by Country (2020-2025)
- 8.4 Europe Retinal Disorders Therapy Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Retinal Disorders Therapy Market Size (2020-2031)
- 9.2 Asia-Pacific Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Retinal Disorders Therapy Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Retinal Disorders Therapy Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Retinal Disorders Therapy Market Size (2020-2031)
- 10.2 South America Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Retinal Disorders Therapy Market Size by Country (2020-2025)
- 10.4 South America Retinal Disorders Therapy Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Retinal Disorders Therapy Market Size (2020-2031)
- 11.2 Middle East & Africa Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Retinal Disorders Therapy Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Retinal Disorders Therapy Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 ALLERGAN
- 12.1.1 ALLERGAN Company Information
- 12.1.2 ALLERGAN Business Overview
- 12.1.3 ALLERGAN Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.1.4 ALLERGAN Retinal Disorders Therapy Product Portfolio
- 12.1.5 ALLERGAN Recent Developments
- 12.2 Alimera Sciences
- 12.2.1 Alimera Sciences Company Information
- 12.2.2 Alimera Sciences Business Overview
- 12.2.3 Alimera Sciences Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.2.4 Alimera Sciences Retinal Disorders Therapy Product Portfolio
- 12.2.5 Alimera Sciences Recent Developments
- 12.3 Bausch & Lomb
- 12.3.1 Bausch & Lomb Company Information
- 12.3.2 Bausch & Lomb Business Overview
- 12.3.3 Bausch & Lomb Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.3.4 Bausch & Lomb Retinal Disorders Therapy Product Portfolio
- 12.3.5 Bausch & Lomb Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.4.4 Bristol-Myers Squibb Retinal Disorders Therapy Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Genentech
- 12.5.1 Genentech Company Information
- 12.5.2 Genentech Business Overview
- 12.5.3 Genentech Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.5.4 Genentech Retinal Disorders Therapy Product Portfolio
- 12.5.5 Genentech Recent Developments
- 12.6 Genzyme
- 12.6.1 Genzyme Company Information
- 12.6.2 Genzyme Business Overview
- 12.6.3 Genzyme Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.6.4 Genzyme Retinal Disorders Therapy Product Portfolio
- 12.6.5 Genzyme Recent Developments
- 12.7 Janssen Biotech
- 12.7.1 Janssen Biotech Company Information
- 12.7.2 Janssen Biotech Business Overview
- 12.7.3 Janssen Biotech Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.7.4 Janssen Biotech Retinal Disorders Therapy Product Portfolio
- 12.7.5 Janssen Biotech Recent Developments
- 12.8 OCULAR THERAPEUTIX
- 12.8.1 OCULAR THERAPEUTIX Company Information
- 12.8.2 OCULAR THERAPEUTIX Business Overview
- 12.8.3 OCULAR THERAPEUTIX Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.8.4 OCULAR THERAPEUTIX Retinal Disorders Therapy Product Portfolio
- 12.8.5 OCULAR THERAPEUTIX Recent Developments
- 12.9 Swedish Orphan Biovitrum
- 12.9.1 Swedish Orphan Biovitrum Company Information
- 12.9.2 Swedish Orphan Biovitrum Business Overview
- 12.9.3 Swedish Orphan Biovitrum Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.9.4 Swedish Orphan Biovitrum Retinal Disorders Therapy Product Portfolio
- 12.9.5 Swedish Orphan Biovitrum Recent Developments
- 12.10 UCBCares
- 12.10.1 UCBCares Company Information
- 12.10.2 UCBCares Business Overview
- 12.10.3 UCBCares Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.10.4 UCBCares Retinal Disorders Therapy Product Portfolio
- 12.10.5 UCBCares Recent Developments
- 12.11 AbbVie
- 12.11.1 AbbVie Company Information
- 12.11.2 AbbVie Business Overview
- 12.11.3 AbbVie Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.11.4 AbbVie Retinal Disorders Therapy Product Portfolio
- 12.11.5 AbbVie Recent Developments
- 12.12 Eyebright Medical
- 12.12.1 Eyebright Medical Company Information
- 12.12.2 Eyebright Medical Business Overview
- 12.12.3 Eyebright Medical Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.12.4 Eyebright Medical Retinal Disorders Therapy Product Portfolio
- 12.12.5 Eyebright Medical Recent Developments
- 12.13 Aier Eye Hospital
- 12.13.1 Aier Eye Hospital Company Information
- 12.13.2 Aier Eye Hospital Business Overview
- 12.13.3 Aier Eye Hospital Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.13.4 Aier Eye Hospital Retinal Disorders Therapy Product Portfolio
- 12.13.5 Aier Eye Hospital Recent Developments
- 12.14 Alcon Holdings, Inc.
- 12.14.1 Alcon Holdings, Inc. Company Information
- 12.14.2 Alcon Holdings, Inc. Business Overview
- 12.14.3 Alcon Holdings, Inc. Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.14.4 Alcon Holdings, Inc. Retinal Disorders Therapy Product Portfolio
- 12.14.5 Alcon Holdings, Inc. Recent Developments
- 12.15 Huaxia Eye Hospital
- 12.15.1 Huaxia Eye Hospital Company Information
- 12.15.2 Huaxia Eye Hospital Business Overview
- 12.15.3 Huaxia Eye Hospital Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.15.4 Huaxia Eye Hospital Retinal Disorders Therapy Product Portfolio
- 12.15.5 Huaxia Eye Hospital Recent Developments
- 12.16 Kanghong Pharmaceutical
- 12.16.1 Kanghong Pharmaceutical Company Information
- 12.16.2 Kanghong Pharmaceutical Business Overview
- 12.16.3 Kanghong Pharmaceutical Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.16.4 Kanghong Pharmaceutical Retinal Disorders Therapy Product Portfolio
- 12.16.5 Kanghong Pharmaceutical Recent Developments
- 12.17 Roche
- 12.17.1 Roche Company Information
- 12.17.2 Roche Business Overview
- 12.17.3 Roche Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.17.4 Roche Retinal Disorders Therapy Product Portfolio
- 12.17.5 Roche Recent Developments
- 12.18 Xingqi Pharmaceutical
- 12.18.1 Xingqi Pharmaceutical Company Information
- 12.18.2 Xingqi Pharmaceutical Business Overview
- 12.18.3 Xingqi Pharmaceutical Revenue in Retinal Disorders Therapy Business (2020-2025)
- 12.18.4 Xingqi Pharmaceutical Retinal Disorders Therapy Product Portfolio
- 12.18.5 Xingqi Pharmaceutical Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Retinal Disorders Therapy Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Retinal Disorders Therapy Revenue Market Share by Type (2020-2025)
- Table 7. Global Retinal Disorders Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Retinal Disorders Therapy Revenue Market Share by Type (2026-2031)
- Table 9. Global Retinal Disorders Therapy Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Retinal Disorders Therapy Revenue Market Share by Application (2020-2025)
- Table 11. Global Retinal Disorders Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Retinal Disorders Therapy Revenue Market Share by Application (2026-2031)
- Table 13. Global Retinal Disorders Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Retinal Disorders Therapy Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Retinal Disorders Therapy Market Share by Region (2020-2025)
- Table 16. Global Retinal Disorders Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Retinal Disorders Therapy Market Share by Region (2026-2031)
- Table 18. Retinal Disorders Therapy Industry Trends
- Table 19. Retinal Disorders Therapy Industry Drivers
- Table 20. Retinal Disorders Therapy Industry Opportunities and Challenges
- Table 21. Retinal Disorders Therapy Market Restraints
- Table 22. Global Top Retinal Disorders Therapy Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Retinal Disorders Therapy Revenue Market Share by Players (2020-2025)
- Table 24. Global Retinal Disorders Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Retinal Disorders Therapy, Headquarters and Area Served
- Table 26. Global Retinal Disorders Therapy Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Retinal Disorders Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Retinal Disorders Therapy Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Retinal Disorders Therapy Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Retinal Disorders Therapy Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Retinal Disorders Therapy Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Retinal Disorders Therapy Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Retinal Disorders Therapy Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Retinal Disorders Therapy Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Retinal Disorders Therapy Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Retinal Disorders Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Retinal Disorders Therapy Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Retinal Disorders Therapy Market Size by Country (2026-2031) & (US$ Million)
- Table 45. ALLERGAN Company Information
- Table 46. ALLERGAN Business Overview
- Table 47. ALLERGAN Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 48. ALLERGAN Retinal Disorders Therapy Product Portfolio
- Table 49. ALLERGAN Recent Developments
- Table 50. Alimera Sciences Company Information
- Table 51. Alimera Sciences Business Overview
- Table 52. Alimera Sciences Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 53. Alimera Sciences Retinal Disorders Therapy Product Portfolio
- Table 54. Alimera Sciences Recent Developments
- Table 55. Bausch & Lomb Company Information
- Table 56. Bausch & Lomb Business Overview
- Table 57. Bausch & Lomb Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 58. Bausch & Lomb Retinal Disorders Therapy Product Portfolio
- Table 59. Bausch & Lomb Recent Developments
- Table 60. Bristol-Myers Squibb Company Information
- Table 61. Bristol-Myers Squibb Business Overview
- Table 62. Bristol-Myers Squibb Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 63. Bristol-Myers Squibb Retinal Disorders Therapy Product Portfolio
- Table 64. Bristol-Myers Squibb Recent Developments
- Table 65. Genentech Company Information
- Table 66. Genentech Business Overview
- Table 67. Genentech Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 68. Genentech Retinal Disorders Therapy Product Portfolio
- Table 69. Genentech Recent Developments
- Table 70. Genzyme Company Information
- Table 71. Genzyme Business Overview
- Table 72. Genzyme Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 73. Genzyme Retinal Disorders Therapy Product Portfolio
- Table 74. Genzyme Recent Developments
- Table 75. Janssen Biotech Company Information
- Table 76. Janssen Biotech Business Overview
- Table 77. Janssen Biotech Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 78. Janssen Biotech Retinal Disorders Therapy Product Portfolio
- Table 79. Janssen Biotech Recent Developments
- Table 80. OCULAR THERAPEUTIX Company Information
- Table 81. OCULAR THERAPEUTIX Business Overview
- Table 82. OCULAR THERAPEUTIX Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 83. OCULAR THERAPEUTIX Retinal Disorders Therapy Product Portfolio
- Table 84. OCULAR THERAPEUTIX Recent Developments
- Table 85. Swedish Orphan Biovitrum Company Information
- Table 86. Swedish Orphan Biovitrum Business Overview
- Table 87. Swedish Orphan Biovitrum Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 88. Swedish Orphan Biovitrum Retinal Disorders Therapy Product Portfolio
- Table 89. Swedish Orphan Biovitrum Recent Developments
- Table 90. UCBCares Company Information
- Table 91. UCBCares Business Overview
- Table 92. UCBCares Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 93. UCBCares Retinal Disorders Therapy Product Portfolio
- Table 94. UCBCares Recent Developments
- Table 95. AbbVie Company Information
- Table 96. AbbVie Business Overview
- Table 97. AbbVie Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 98. AbbVie Retinal Disorders Therapy Product Portfolio
- Table 99. AbbVie Recent Developments
- Table 100. Eyebright Medical Company Information
- Table 101. Eyebright Medical Business Overview
- Table 102. Eyebright Medical Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 103. Eyebright Medical Retinal Disorders Therapy Product Portfolio
- Table 104. Eyebright Medical Recent Developments
- Table 105. Aier Eye Hospital Company Information
- Table 106. Aier Eye Hospital Business Overview
- Table 107. Aier Eye Hospital Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 108. Aier Eye Hospital Retinal Disorders Therapy Product Portfolio
- Table 109. Aier Eye Hospital Recent Developments
- Table 110. Alcon Holdings, Inc. Company Information
- Table 111. Alcon Holdings, Inc. Business Overview
- Table 112. Alcon Holdings, Inc. Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 113. Alcon Holdings, Inc. Retinal Disorders Therapy Product Portfolio
- Table 114. Alcon Holdings, Inc. Recent Developments
- Table 115. Huaxia Eye Hospital Company Information
- Table 116. Huaxia Eye Hospital Business Overview
- Table 117. Huaxia Eye Hospital Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 118. Huaxia Eye Hospital Retinal Disorders Therapy Product Portfolio
- Table 119. Huaxia Eye Hospital Recent Developments
- Table 120. Kanghong Pharmaceutical Company Information
- Table 121. Kanghong Pharmaceutical Business Overview
- Table 122. Kanghong Pharmaceutical Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 123. Kanghong Pharmaceutical Retinal Disorders Therapy Product Portfolio
- Table 124. Kanghong Pharmaceutical Recent Developments
- Table 125. Roche Company Information
- Table 126. Roche Business Overview
- Table 127. Roche Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 128. Roche Retinal Disorders Therapy Product Portfolio
- Table 129. Roche Recent Developments
- Table 130. Xingqi Pharmaceutical Company Information
- Table 131. Xingqi Pharmaceutical Business Overview
- Table 132. Xingqi Pharmaceutical Revenue in Retinal Disorders Therapy Business (2020-2025) & (US$ Million)
- Table 133. Xingqi Pharmaceutical Retinal Disorders Therapy Product Portfolio
- Table 134. Xingqi Pharmaceutical Recent Developments
- Table 135. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Retinal Disorders Therapy Product Image
- Figure 5. Global Retinal Disorders Therapy Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Retinal Disorders Therapy Market Share by Type: 2024 VS 2031
- Figure 7. Ocular Inflammatory Disease (Uveitis) Product
- Figure 8. Diabetic Retinopathy Product
- Figure 9. Age Related Macular Degeneration Product
- Figure 10. Macular Hole Product
- Figure 11. Global Retinal Disorders Therapy Market Size by Application (2025-2031) & (US$ Million)
- Figure 12. Global Retinal Disorders Therapy Market Share by Application: 2024 VS 2031
- Figure 13. Hospitals Product
- Figure 14. Clinics Product
- Figure 15. Others Product
- Figure 16. Global Retinal Disorders Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 17. Global Retinal Disorders Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 18. Global Retinal Disorders Therapy Market Share by Region: 2024 VS 2031
- Figure 19. Global Retinal Disorders Therapy Market Share by Players in 2024
- Figure 20. Global Retinal Disorders Therapy Manufacturers Established Date
- Figure 21. Global Top 5 and 10 Retinal Disorders Therapy Players Market Share by Revenue in 2024
- Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 23. North America Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 24. North America Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 25. United States Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 26. Canada Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 27. Mexico Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 28. Europe Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 29. Europe Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 30. Germany Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 31. France Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 32. U.K. Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 33. Italy Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 34. Spain Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 35. Russia Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. Netherlands Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. Nordic Countries Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Asia-Pacific Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Asia-Pacific Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 40. China Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 41. Japan Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 42. South Korea Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. India Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 44. India Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 45. Australia Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 46. China Taiwan Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. South America Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 49. South America Retinal Disorders Therapy Market Share by Country (2020-2031)
- Figure 50. Brazil Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 51. Argentina Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 52. Chile Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. Colombia Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 54. Peru Retinal Disorders Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 55. ALLERGAN Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 56. Alimera Sciences Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 57. Bausch & Lomb Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 59. Genentech Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 60. Genzyme Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 61. Janssen Biotech Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 62. OCULAR THERAPEUTIX Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 63. Swedish Orphan Biovitrum Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 64. UCBCares Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 65. AbbVie Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 66. Eyebright Medical Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 67. Aier Eye Hospital Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 68. Alcon Holdings, Inc. Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 69. Huaxia Eye Hospital Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 70. Kanghong Pharmaceutical Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 71. Roche Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
- Figure 72. Xingqi Pharmaceutical Revenue Growth Rate in Retinal Disorders Therapy Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


